Mesoblast
MESO
Performance
About Mesoblast
Mesoblast is an innovative biotechnology company specializing in the development and commercialization of allogeneic cellular medicines aimed at treating serious inflammatory diseases that currently have high unmet medical needs. Headquartered in Australia and listed on both the ASX and Nasdaq, the company is advancing several Phase 3 therapies, including RYONCIL™ for acute graft versus host disease, Remestemcel-L for COVID-19 related acute respiratory distress syndrome, REVASCOR® for chronic heart failure, and MPC-06-ID for chronic low back pain. With an extensive patent portfolio and rigorous research protocols, Mesoblast is committed to ensuring the safety and efficacy of its products for patients globally.
Recent News
2026 Predictions: Historic FDA Shift, Plausible Mechanisms, Bespoke Tx, RFK Jr., Biotechs, State AGs, Peptides, Embryos
Grading My 25 Stem Cell & Regenerative Medicine Predictions for 2025
Why Silo Pharma Shares Are Trading Higher By Around 52%; Here Are 20 Stocks Moving Premarket
Harmeier Returns to Lead Roche Venture Fund
Recent Deals
No recent deals for this company.
